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Background: Understanding patients’ views about medication is crucial to maximize adherence. Thalassemia is a
congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy.
Methods: The Beliefs in Medicine Questionnaire (BMQ) was used to assess beliefs in chelation in thalassemia
patients from North America and London in the Thalassemia Longitudinal Cohort (TLC) of the Thalassemia Clinical
Research Network (TCRN). Chelation adherence was based on patient report of doses administered out of those
prescribed in the last four weeks.
Results: Of 371 patients (ages 5-58y, mean 24y), 93% were transfused and 92% receiving chelation (26%
deferoxamine (DFO; a slow subcutaneous infusion via portable pump), 63% oral, 11% combination). Patients
expressed high “necessity” for transfusion (96%), DFO chelation (92%) and oral chelation (89%), with lower “concern”
about treatment (48%, 39%, 19% respectively). Concern about oral chelation was significantly lower than that of
DFO (p<0.001). Self-reported adherence to chelation was not associated with views about necessity or concerns,
but negatively correlated with perceived sensitivity to DFO (Sensitive Soma scale; r=−0.23, p=0.01) and side effects
of oral chelation (r=−0.14, p=0.04). High ferritin iron levels, potentially indicating lower adherence, were found in
41% of patients reporting low necessity of oral chelation compared to 24% reporting high necessity (p=0.048).
Concerns about treatment were associated with lower quality of life and more symptoms of anxiety and
depression.
Conclusions: Despite their requirement for multimodal therapy, thalassemia patients have positive views about
medicine, more so than in other disease populations. Patients may benefit from education about the tolerability of
chelation and strategies to effectively cope with side effects, both of which might be beneficial in lowering body
iron burden.
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Thalassemia is a congenital blood disorder that is often
managed with chronic blood transfusions, typically every
2–4 weeks, which leads to progressive iron overload.
Daily iron chelation therapy is prescribed to manage the
transfusional iron overload and attempt to prevent pro-
gressive organ failure (heart, endocrine, liver). Life ex-
pectancy is directly related to the quality of chelation* Correspondence: FTrachtenberg@neriscience.com
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distribution, and reproduction in any mediumtherapy, and poor adherence to treatment increases the
risk of complications and shortens survival. Patient ad-
herence practices are generally seen as a singular action,
a one-dimensional phenomenon where the patient sim-
ply chooses not to do their chelation therapy. In this
model, either simpler chelation methods and/or patient
education were the defined solutions to failed practice.
Until recently, parenteral treatment with nearly daily
prolonged infusion of deferoxamine was the only avail-
able treatment, However, despite the development of new
oral chelators and the development of patient educationentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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lem in thalassemia. Developing effective adherence inter-
ventions requires better analytic models of adherence
practice.
Patients’ concerns about their treatments and their
beliefs in its necessity appear to be critical in under-
standing patient adherence practices. The Beliefs about
Medicines Questionnaire (BMQ) was designed to exam-
ine this and has been used in many disease populations,
including asthma, diabetes, renal disease, cardiac disease,
oncology, hypertension, arthritis, bowel disease, HIV,
migraines, depression, and psychiatric disorders [1-15].
A second instrument, the Sensitive Soma Assessment
Scale (SSAS) is another instrument that is designed to
assess a patient’s perceived sensitivity to medicines, and
this preconception is likely related to the report of side-
effects [16].
The BMQ scales have been found to correlate with
adherence to treatment across many diseases and popu-
lations [1-14,17,18]. Beliefs that treatment is less neces-
sary or feelings of greater concerns about treatment
are associated with lower adherence to that treatment.
The necessity-concerns difference score has been found
to be especially related to adherence, suggesting that
“medication beliefs were more powerful predictors of
reported adherence than the clinical and sociodemo-
graphic factors” [2]. The SSAS is a new instrument that
early use in AIDS, hypertension, travel clinic, and under-
graduate students suggests has a strong predictive asso-
ciation with adherence [16]. Given the importance of
adherence to thalassemia treatment, understanding how
patients’ beliefs in chelation therapy relate to their adher-
ence (or lack thereof ) may help providers better assist
their patients. This is especially important because chela-
tion therapy has two main forms: subcutaneous slow
infusions by a portable pump (deferoxamine) and oral
(deferasirox, deferiprone).
The Thalassemia Clinical Research Network (TCRN) is
an NIH/NHLBI-funded network composed of five core
thalassemia centers in North America, one in London,
and their associated satellite sites. In May 2007, the
TCRN launched the Thalassemia Longitudinal Cohort
(TLC) study with baseline and annual collection of
patient questionnaires, clinical history, results of standard-
of-care procedures, and data regarding treatments for
thalassemia and its complications. The aim of the present
study is to summarize Beliefs in Medicine Questionnaire
(BMQ) results for patients with thalassemia, compare
beliefs in deferoxamine (DFO) vs. oral chelators, and
assess effect on quality of life, anxiety, depression, and
chelation adherence. This unique large international
study of thalassemia patients spanning a wide age range
(5–58 years) is the first to examine the medical beliefs
of patients with thalassemia. Given the thalassemialiterature which has emphasized the need for better
education to improve adherence, we hypothesized that
patients who viewed chelation as high necessity would
show better adherence, and patients with high concern
would show poorer adherence.
Methods
The TCRN TLC protocol was approved by the TCRN
Data and Safety Monitoring Board and by the ethical re-
view boards of all TCRN institutions. Informed consent
was obtained for all participants. Eligibility for the TLC
study included patients with all thalassemia syndromes
who required at least annual monitoring for end-organ
injury related to thalassemia. 428 patients were enrolled
in the TLC from 2007–2009. Patients with a prior suc-
cessful hematopoietic stem cell transplant (N=12) were
excluded from this analysis. 371 patients completed the
BMQ at baseline and were included in this analysis.
At baseline and annually, demographic information
was collected and participants (age 14+) and/or their par-
ents (age <16y) asked to complete the BMQ (Appendix 1).
Participants were surveyed about their general beliefs in
medicine, and also those specific to transfusion and
chelation. The BMQ is a validated instrument [1,19]
containing 5 scales (Appendix 1), each with 4–5 items:
(1) General-Overuse, (2) General-Harm, (3) General-
Benefit, (4) Specific-Necessity, and (5) Specific-Concerns.
The first three relate to general beliefs in medicine: (1)
the notion that doctors tend to overuse and trust medi-
cines too much, (2) the potential for medicines to be
harmful, addictive, and poisonous, and (3) the potential
for medicines to be helpful and allow for longer better
lives. The last two scales (Specific-Necessity, Specific-
Concerns) apply to the particular medicine the person
is taking and measure how necessary the patient feels
their medicine is for them (necessity), and perceptions
of the potential negative consequences of the medica-
tion such as long-term effects, dependence, and disrup-
tiveness (concerns). Higher necessity scores indicate
higher beliefs that transfusion/chelation is necessary for
their health. Higher concern scores indicate higher levels
of concern about treatment. Participants not on transfu-
sion or chelation therapy completed only the general
scales. Participants on chelation were surveyed about the
specific chelator they were using. Participants were using
a range of chelators, including deferoxamine (DFO),
deferasirox, deferiprone (available only for compassion-
ate use in North America), and combination therapy.
Patients on combination chelation (both DFO and an
oral chelator) completed the scales twice, once for each
chelator. The same survey also included the Sensitive
Soma scale [1,16], 5 items that assess perceptions of per-
sonal sensitivity to the potential adverse effects of medi-
cation (Appendix 1). In addition, a single item from the
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patients can cope without transfusion/chelation. Finally,
one additional item was added asking about unpleasant
side effects of transfusion/chelation. All questions were
asked on a 5-point Likert scale of strongly disagree to
strongly agree (Appendix 1).
Participants aged 14 and older were asked to complete
the hospital anxiety and depression scale (HADS) [20],
as well as the SF-36v2 health survey [21] which mea-
sures health-related quality of life (QOL) in 8 subscales
and two summary scores: physical component and mental
component. Parents of children <14 years at baseline
were asked to complete the PF-28 child health question-
naire (CHQ) [22], which measures quality of life (QOL)
in children in 12 subscales and two summary scores
(physical and mental). Participants or their parents were
surveyed about their chelation use (number of doses
taken in the past week and month), and study coordina-
tors recorded the prescribed chelator dosage. Chelation
adherence was defined as percent of doses administered
in the last four weeks (patient report) out of those pre-
scribed (coordinator chart review). Finally, serum ferritin,
liver iron concentration (LIC) by FerriScanW, MRI,
SQUID, or liver biopsy, and clinical complications were
recorded from chart review. Ferritin ≥2500 ng/ml and
LIC ≥15 mg Fe/g dry were considered markers of inad-
equate chelation. Potential complications included car-
diac complications (congestive heart failure, ventricular
arrhythmia, low cardiac T2*<12 ms by MRI), endocrine
complications (diabetes type I, diabetes type II, growth
hormone deficiency, hypothyroidism, hypoparathyroidism,
hypogonadotropic hypogonadism), liver disease (cirrhosis),
and transfusion related complications and infections
(alloimmunization, active hepatitis C, chronic active
hepatitis B, HIV).Statistical analysis
This manuscript reports baseline data from this ongoing
study, except for the analysis of changes over time and
the analysis of forms completed by both child and parent
in the same family, which included all available follow-
up. Statistical analyses were performed with SAS 9.2 for
Windows (SAS Institute Inc., Cary, NC, USA), and in all
analyses p<0.05 was considered statistically significant.
BMQ scales were scored according to the BMQ scoring
instructions (Appendix 1) and internal consistency mea-
sured with Cronbach’s alpha. Consistent with the devel-
opment of the scales [2], high necessity and concerns
were defined as scores above the midpoint, and four
groups were defined: accepting (high necessity, low con-
cerns), ambivalent (high necessity, high concerns), indif-
ferent (low necessity, low concerns), and skeptical (low
necessity, high concerns) [11]. The necessity-concernsdifference score was calculated and those with a negative
difference score were considered an important subset [2].
To test for differences in beliefs between children and
their parents (N=30 pairs), paired t-tests were used. To
test for differences in beliefs regarding transfusion vs. che-
lation and DFO vs. oral chelation, t-tests were used; parti-
cipants on combination chelation (both DFO and oral)
were excluded from analysis of DFO vs. oral chelation. A
multivariate analysis of covariance model with backwards
elimination was used to model predictors of beliefs
about medicine. Potential predictors included respondent
(parent vs. self ), age group of the patient (child 5–17 years,
young adult 18–24, adult 25+), oral chelator (deferasirox
vs. deferiprone), monotherapy vs. combination chelation
(DFO, oral, combination), gender, race (White, Asian,
other), country (US, Canada, UK), diagnosis (β vs. E-β
thalassemia), regular transfusion (at least 8 transfusions
in the past year), and number of clinical complications.
Correlations between BMQ scales were calculated, as
well as correlations with QOL summary scales, HADS
scales (anxiety, depression), self-reported adherence, and
average ferritin and LIC in the past year (both log-
transformed due to skew). Correlations with adherence,
ferritin, and LIC were also calculated in the subset of
adults (18+), as children are often not in control of their
adherence. Analysis of variance (ANOVA) was used to
compare adherence rates by high/low necessity and con-
cerns, as well as negative/non-negative necessity concerns
difference. Chi-square and Fisher exact tests examined
associations between high/low necessity and concerns
with high ferritin (≥2500 ng/ml) and LIC (≥15 mg Fe/g
dry). To assess changes in BMQ responses over time,
change in each scale from baseline was computed.
Repeated measures models were used to test for linear
changes over follow-up. Finally, t-tests were used to test
for changes over time in individuals who changed chela-
tors during follow-up (DFO to oral or vice versa).
Results
At baseline, 371 TLC participants/parents completed the
BMQ. Surveys were completed by 231 adult participants,
104 parents/guardians (mean age 10.2y, range 5–16) and
49 children (mean age 14.9y, range 10–17), including
30 pairs with forms completed by both child and parent
(13 at baseline and 17 at annual follow-up, all ages 14–15).
Most participants were on transfusion (93%) and chelation
(92%) therapy, with 24% chelating with DFO, 58% on an
oral chelator, and 10% on combination therapy (Table 1).
Patients from London constituted 53% of TLC partici-
pants on deferiprone monotherapy and 27% of those on
deferiprone combination chelation. The participants ran-
ged in age from 5–58 years, with an average of 24 years.
Approximately 75% of respondents had beta thalassemia
major (transfused at least 8 times in the past year).
Table 1 Demographics for the Thalassemia Longitudinal
Cohort (TLC) participants completing the Beliefs in
Medicines Questionnaire (BMQ) (N=371) a












Thalassemia diagnosis, N (%)
β-thal transfused 8+ times 279 (75.2%)
β-thal transfused <8 times 28 (7.6%)
β-thal not transfused 4 (1.1%)
E-β-thal transfused 8+ times 32 (8.6%)
E-β-thal transfused <8 8 (2.2%)
E-β-thal not transfused 1 (0.3%)
HbH 6 (1.6%)




Deferoxamine (DFO) 89 (24.0%)
Deferasirox 200 (53.9%)
Deferiprone 15 (4.0%)
Deferoxamine + Deferasirox 11 (3.0%)
Deferoxamine + Deferiprone 26 (7.0%)
Serum ferritin (ng/ml), median (range) b 1296.8 (75.0 - 18453.5)
Liver iron concentration (LIC in mg Fe/g dry),
median (range) b
8.2 (0.4 – 67.9)
a The questionnaire was completed by the parents of younger children.
b N=355 for ferritin and N=251 for LIC. 24% had ferritin≥2500 ng/ml and 24%
had LIC≥15 mg/g.
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(median 1, range 0–8, 21% with >2 complications). In-
ternal consistency (Cronbach’s alpha) for all BMQ scales
was within the range reported in scale development
[1,16]: 0.80-0.84 for the Specific-Necessity scales, 0.68-
0.73 for the Specific-Concerns scales, 0.63-0.71 for the
general scales, and 0.84 for Sensitive Soma.
BMQ scales for transfusion and chelation
Of those on transfusion therapy, 96% reported high
necessity (> midpoint of 15 points), with 48% reportinghigh concerns. For chelation therapy, high necessity was
reported in 92% of those on DFO and 89% of those on
oral chelation, with concerns reported in 39% and 19%
respectively. Participants rated significantly higher the
necessity of transfusion compared to chelation (paired
t-test, p<0.001 for both DFO and oral chelation), with
no specific items responsible for this difference and no
significant difference between transfusion and DFO
chelation on the Specific-Concerns scale. There were
no significant differences found on reported ability to
cope without transfusion, DFO, or oral chelation. How-
ever, greater side effects were reported for DFO com-
pared to transfusion and oral chelation (p≤0.001 for
both).
There was no significant difference between chelators
on the Specific-Necessity scale, but participants expressed
higher concern about chelation with DFO compared to
oral chelation (p<0.001, Table 2), with an increase of
1.74 ± 0.48 points largely stemming from responses to
the item on “disruption to life”. Participants on DFO
compared to oral chelation perceived their bodies to be
more sensitive to medications (Sensitive Soma scale
12.9 vs. 11.1, p<0.001). There were no differences in
beliefs between patients on deferasirox vs. deferiprone.
However, patients on combination therapy reported lower
beliefs in the necessity of each chelator compared to
patients on monotherapy (p≤0.002 for both DFO and
oral chelation, Table 3).
Few participants had higher concerns than necessity
(0.9% for transfusion and 6% for each type of chelator).
Views about DFO and oral chelation, respectively, were
56% and 73% accepting (high necessity, low concerns),
36% and 16% ambivalent (high necessity, high concerns),
5% and 8% indifferent (low necessity, low concerns), and
3% and 4% skeptical (low necessity, high concerns).
Predictors of BMQ scales
Parents expressed significantly higher levels of necessity
and concern about oral chelation compared to children,
as well as higher beliefs in the general benefit of medi-
cines (Tables 2, 3). The largest difference on a specific
item was worrying about long-term effects (3.40 vs. 4.26
for DFO; 2.59 vs. 3.47 for oral chelation). In analysis of
the 30 pairs of parent/child reporters, all children aged
14-15y, parents reported significantly higher levels of
concern about oral chelation; there was a similar trend
for necessity of oral chelation and general benefit, which
was non-significant, possibly due to small sample size.
Many of the BMQ scale scores also increased signifi-
cantly with age (Table 3). Belief in the necessity of oral
chelation was higher in adults and young adults com-
pared to children. Concerns about oral chelation were
higher in adults aged 25+ compared to children. On the
other hand, concerns about DFO were higher in children
Table 2 Beliefs in Medicines Questionnaire (BMQ) scale responses by age groupa and respondent
BMQ Scale Na Mean (SD)
Child Young Adult Adult Parent of Child
Age 10–17 N=49 Age 18–24 N=75 Age 25+ N=156 Age 5–16 N=104
Specific Necessity–DFOb 132 21.0 (3.3) 20.5 (3.4) 21.6 (3.7) 21.3 (3.1)
Specific Concerns–DFOc 131 14.4 (5.0) 12.1 (4.2) 12.9 (3.5) 16.7 (2.8)
Specific Necessity-Oral Chelatorb 256 19.0 (3.9) 20.2 (3.9) 20.9 (3.8) 21.4 (3.4)
Specific Concerns-Oral Chelatorc 256 10.8 (3.6) 11.8 (3.9) 12.2 (3.6) 13.0 (4.0)
General Overused 375 11.6 (2.5) 11.8 (2.8) 11.8 (2.8) 12.2 (2.9)
General Harme 380 9.5 (2.4) 9.3 (2.7) 8.9 (2.8) 9.6 (3.2)
General Benefitf 378 15.6 (2.3) 15.7 (2.1) 15.9 (2.4) 16.3 (2.2)
Sensitive Somag 379 11.3 (3.9) 11.4 (3.8) 12.0 (3.9) 11.7 (3.7)
Comparison of DFO vs. Oral Chelation across age groups
BMQ Scale Specific Necessity Specific Concerns General Overuse General Harm General Benefit Sensitive Soma
p-valueh 0.30 <0.001 0.08 0.20 0.08 <0.001
a includes 13 parent/child pairs of responses from the same family.
b 5 items measuring how necessary participants perceive chelation to be. Higher scores indicate higher perceived necessity (0–25 points). Participants on both
DFO and oral chelation responded separately for each chelator.
c 5 items measuring participants’ concerns with chelation. Higher scores indicate higher levels of concern (0–25 points). Participants on both DFO and oral
chelation responded separately for each chelator.
d 4 items measuring beliefs that doctors tend to overuse and trust medicines too much. Higher scores indicate higher levels of this belief in the overuse of
medicines (0–20 points).
e 4 items measuring beliefs that medicines tend to be harmful, addictive, and poisonous. Higher scores indicate higher levels of this belief in the harm of
medicines (0–20 points).
f 4 items measuring beliefs that medicines are helpful and make people live longer better lives. Higher scores indicate higher levels of this belief in the benefit of
medicines (0–20 points).
g 5 items measuring perceptions of personal sensitivity to the potential adverse effects of medication. Higher scores indicate higher levels of this perception of
sensitivity to medicines (0–25 points).
h Across all ages and respondents, t-test for DFO vs. oral chelation, excluding participants on both. Participants on DFO compared to oral chelation report belief in
slightly higher General Overuse (12.4 vs. 11.8) and General Harm (9.4 vs. 9.0), slightly lower General Benefit (15.6 vs. 16.1), and significantly higher Sensitive Soma
(12.9 vs. 11.1).
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aged 25+ scored lower on the General-Harm scale com-
pared to young adults and children, indicating lower be-
lief that medicines are harmful.
Predictors of beliefs in medicine responses are sum-
marized in Table 3. There were few gender differences
on BMQ scales, but many racial differences. Asians par-
ticipants reported higher levels of concern about chela-
tion compared to White participants. Participants of
other races reported lower levels of concern about DFO,
but higher levels of concern and lower levels of neces-
sity for oral chelation compared to White participants.
Participants of other races also scored higher on the
General-Overuse and General-Harm scales, and lower
on the General-Benefit scale, compared to White parti-
cipants. Furthermore, there were several differences in
BMQ scores between participants in different countries.
American participants reported lower levels of concern
about DFO compared to those in Canada and the UK.
Canadians scored higher on the General-Overuse scale
compared to Americans. Additionally, participants in the
UK scored higher on the General-Harm scale, but higher
on the Specific-Necessity of oral chelation compared to
Americans and Canadians. Regularly transfused patientsreported a higher necessity of DFO chelation. Higher
numbers of clinical complications were associated with
higher necessity of DFO and higher Sensitive Soma score.
Associations between BMQ scales and with chelation
adherence and quality of life
Higher beliefs in the overuse and harm of medicines were
correlated with concern about treatments, and higher
beliefs in the benefit of medicines were correlated with
beliefs in the necessity of treatments (Table 4). Not sur-
prisingly, those who believed their bodies to be more
sensitive to medicines (Sensitive Soma) reported higher
levels of concern about their treatments, higher beliefs in
the overuse and harm of medicines (r=0.24 and 0.23;
p<0.001), and lower beliefs in the benefit of medicines
(r=−0.17, p<0.001). Those experiencing more side effects
felt more concern about their treatments and higher
sensitivity to medicines (r=0.13-0.36). Having fewer con-
cerns about treatment was generally associated with
higher quality of life (QOL) and fewer symptoms of
anxiety and depression. On the other hand, belief in
bodily sensitivity to medicines was associated with lower
QOL (r=−0.22 - −0.44; p<0.01) and higher symptoms of
anxiety and depression (r=0.21, p<0.001 for both).
Table 3 Predictors of Beliefs in Medicines Questionnaire
(BMQ) scale responses a
Slope (SE) p-value
Predictors of Specific Necessity - DFO
Monotherapy vs. combination therapy 2.39 (0.75) 0.002
Regularly transfused 2.84 (1.02) 0.006
Number of complications 0.39 (0.18) 0.031
Predictors of Specific Concerns - DFO
Age group 0.04
Young adult vs. child −2.45 (0.95)
Adult vs. child −1.87 (0.99)
Race <0.001
Asian vs. white 1.91 (0.66)
Other vs. white −5.25 (2.15)
Country 0.004
Canada vs. US 1.89 (0.93)
UK vs. US 2.80 (1.03)
Predictors of Specific Necessity – Oral Chelator
Monotherapy vs. combination therapy 3.47 (0.66) <0.001
Parent vs. self 1.06 (0.53) 0.048
Race <0.001
Asian vs. white −0.19 (0.46)
Other vs. white −3.74 (1.01)
Country 0.002
Canada vs. US 0.31 (0.68)
UK vs. US 2.49 (0.72)
Predictors of Specific Concerns - Oral Chelator
Parent vs. self 2.61 (0.77) 0.001
Age group 0.005
Young adult vs. child 1.42 (0.80)
Adult vs. child 2.39 (0.74)
Race <0.001
Asian vs. white 1.63 (0.49)
Other vs. white 2.94 (1.01)
Female vs. male −1.19 (0.46) 0.01
Predictors of General Overuse
Race 0.006
Asian vs. white 0.26 (0.30)
Other vs. white 2.01 (0.62)
Country 0.05
Canada vs. US 0.90 (0.37)
UK vs. US 0.48 (0.48)
Predictors of General Harm
Age group 0.04
Young adult vs. child −0.20 (0.40)
Adult vs. child −0.91 (0.37)
Table 3 Predictors of Beliefs in Medicines Questionnaire
(BMQ) scale responses a (Continued)
Race 0.02
Asian vs. white 0.19 (0.31)
Other vs. white 1.76 (0.64)
Country 0.007
Canada vs. US 0.03 (0.39)
UK vs. US 1.64 (0.52)
Predictors of General Benefit
Parent vs. self 0.62 (0.27) 0.02
Race 0.03
Asian vs. white 0.08 (0.25)
Other vs. white −1.33 (0.53)
Predictors of Sensitive Soma
Number of complications 0.29 (0.12) 0.02
a Multivariate analysis of covariance model with backwards elimination.
Predictors: respondent (parent vs. self), age group (child 5–17, young adult
18–24, adult 25+), gender, race (White, Asian, other), country (US, Canada, UK),
diagnosis (β vs. E-β thal), regularly transfused (at least 8 transfusions in the
past year), and number of complications (congestive heart failure, ventricular
arrhythmia, low cardiac T2* by MRI, type I or II diabetes, growth hormone
deficiency, hypothyroidism, hypoparathyroidism, hypogonadotropic
hypogonadism, cirrhosis, alloimmunization, active hepatitis C, chronic active
hepatitis B, and HIV).
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and 95.5% to oral chelation (95.6% deferasirox, 94.5%
deferiprone), with 76.1% and 87.8% reporting at least
90% adherence, respectively. Surprisingly, adherence to
chelation was not associated with beliefs in the necessity
of nor concerns about chelation, for either DFO or oral
chelation (Table 4). There were also no such trends
when analysis was restricted to adults. Adherence was
also not associated with the necessity-concerns difference
score, a measure of the patients’ cost-benefit analysis
(r=−0.05, p=0.57 for DFO; r=0.08, p=0.21 for oral chela-
tion; similar correlations for adults), and did not vary by
high/low necessity or concerns or negative/non-negative
necessity-concerns difference. On the other hand, aver-
age ferritin and LIC over the past year positively corre-
lated with concerns about oral chelation (Table 4), and
negatively with the necessity-concerns difference score
(r=−0.13, p=0.04 for ferritin; r=−0.13, p=0.09 for LIC).
High ferritin (≥2500) was found in 24% of patients
reporting high necessity of oral chelation compared to
41% reporting low necessity (p=0.048) and 39% reporting
high concerns vs. 23% reporting low concerns (p=0.03).
Self-reported adherence negatively correlated with per-
ceived bodily sensitivity to DFO (Sensitive Soma) and
with side effects from oral chelation (Table 4).
Changes in BMQ scores over time
BMQ scores were generally stable over time, with aver-
age differences from baseline within one point in either
Table 4 Correlations of Beliefs in Medicines Questionnaire (BMQ) scale responses to quality of life and chelation adherence
DFO Oral Chelator Iron Burden
Specific Necessity Specific Concerns Adherencef Specific Necessity Specific Concerns Adherencef Ferriting LICg
General Overuse 0.04 (p=0.66) 0.29 (p<0.001) −0.09 (p=0.30) −0.13 (p=0.04) 0.32 (p<0.001) −0.11 (p=0.10) 0.10 (p=0.06) 0.13 (p=0.04)
General Harm 0.01 (p=0.95) 0.42 (p<0.001) −0.11 (p=0.23) −0.13 (p=0.03) 0.35 (p<0.001) −0.12 (p=0.07) 0.12 (p=0.02) 0.21 (p<0.001)
General Benefit 0.30 (p<0.001) 0.04 (p=0.64) 0.19 (p=0.03) 0.37 (p<0.001) −0.05 (p=0.46) −0.002 (p=0.97) 0.02 (p=0.73) 0.03 (p=0.64)
Sensitive Soma −0.02 (p=0.79) 0.17 (p=0.05) −0.23 (p=0.01) −0.09 (p=0.14) 0.35 (p<0.001) −0.09 (p=0.15) 0.01 (p=0.89) 0.01 (p=0.82)
Coping w/o Treatmenta −0.27 (p=0.002) −0.001 (p=0.98) 0.01 (p=0.95) −0.44 (p<0.001) 0.16 (p=0.01) −0.12 (p=0.08) NA NA
Side Effectsb −0.16 (p=0.06) 0.50 (p<0.001) −0.11 (p=0.23) −0.03 (p=0.65) 0.46 (p<0.001) −0.14 (p=0.04) NA NA
QOL Physical – adultsc −0.11 (p=0.26) −0.16 (p=0.11) NA −0.06 (p=0.45) −0.19 (p=0.008) NA NA NA
QOL Mental – adultsc 0.06 (p=0.55) −0.10 (p=0.31) NA −0.11 (p=0.14) −0.23 (p=0.001) NA NA NA
QOL Physical – childrend 0.26 (p=0.19) −0.04 (p=0.83) NA −0.01 (p=0.95) −0.34 (p=0.006) NA NA NA
QOL Mental – childrend 0.04 (p=0.85) −0.49 (p=0.01) NA 0.09 (p=0.50) −0.38 (p=0.002) NA NA NA
Anxietye 0.02 (p=0.82) 0.19 (p=0.06) NA 0.04 (p=0.58) 0.29 (p<0.001) NA NA NA
Depressione 0.07 (p=0.46) 0.34 (p<0.001) NA 0.04 (p=0.59) 0.28 (p<0.001) NA NA NA
Chelation Adherencef −0.10 (p=0.28) −0.01 (p=0.91) NA 0.03 (p=0.63) −0.09 (p=0.18) NA NA NA
Ferriting 0.12 (p=0.17) −0.21h (p=0.02) −0.28 (p=0.002) −0.06 (p=0.39) 0.14 (p=0.03) −0.25 (p<0.001) NA NA
LICg −0.04 (p=0.66) −0.06 (p=0.56) −0.09 (p=0.39) −0.04 (p=0.57) 0.14 (p=0.06) −0.22 (p=0.004) NA NA
a single item asking how well patients can cope without their chelation (1–5 scale).
b single item asking about unpleasant side effects of chelation (1–5 scale).
c Physical and Mental Component Summary scales of the SF-36v2 quality of life (QOL) health survey, completed by participants aged 14 and older. Higher scores indicate higher QOL.
d Physical Summary and Psychosocial Summary scales of the PF-28 child health questionnaire (CHQ) , completed by parents/guardians of participants <14 years of age. Higher scores indicate higher QOL.
e Anxiety and depressions scales of the Hospital Anxiety and Depression Scale (HADS), completed by participants aged 14 and older. Higher scores indicate increased anxiety/depression.
f Self-reported (or parent-reported) percent of prescribed doses taken in the last 4 weeks.
g Serum ferritin and Liver iron concentration (LIC) averaged over past year, log-transformed due to skew.
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time was a small decrease in reported concerns about
DFO (slope = −0.72, p=0.006), which was no longer sig-
nificant if analysis was restricted to those participants
who remained on DFO (slope = −0.47, p=0.20). Among
participants who switched from DFO to oral chelation
during TLC follow-up (N=40), concerns about their che-
lator decreased by 1.76 points (p=0.02). There was no
trend towards change in BMQ for those who switched
from oral chelation to DFO (N=13).
Discussion
In this first study to look at beliefs about medication in
thalassemia, most participants viewed their thalassemia
treatment of transfusion and chelation as very necessary.
As expected, their views about concerns were less uniform;
having concerns about extensive and invasive treatment
can be normal. Nonetheless, these patients generally
reported higher beliefs in necessity and lower concerns
about their treatment when compared to populations with
other diseases [1-3]. Necessity of chelation was similar to
that reported for disease-specific medications by diabetic
patients [1] and higher than those of patients with asthma,
renal disease, cardiac disease, cancer, psychiatric illness, and
rheumatoid arthritis [1-3]. Concerns about DFO chelation
were similar to concerns about medications in diabetic [1]
and oncology patients [2], and lower than all other diseases
reported [1-3]; concerns about oral chelation were the low-
est of any disease population [1-3]. As blood transfusions
are life-sustaining for patients with the more severe forms
of thalassemia, it is perhaps not surprising that they view
transfusion as more necessary than chelation. Patients im-
mediately feel their response to transfusion with improve-
ment in physical symptoms (e.g., asthenia, back pain). This
is in contrast to iron overload which leads to insidious
complications without overt symptoms for years. Neverthe-
less, the high ratings of necessity of chelation are a positive
indication that patients understand the benefit of chelation
and/or the health consequences of not chelating. This is
important because providers do make the effort to educate
patients about the necessity of chelation.
Views about chelation
It is encouraging that regularly transfused patients and
those with more complications are especially aware of
the necessity of chelation. The higher concerns about
DFO compared to oral chelation likely reflects the
method of administration of DFO and its disruptiveness
to their life. The higher reported sensitivity to medicines
of those on DFO compared to oral chelation might also
reflect greater disruption DFO has on patient daily life.
Indeed, patients who switched from DFO to oral chela-
tion reported decreased concerns, despite the fact that
BMQ scores on all scales were generally stable overtime. This is consistent with a previous study showing
that BMQ General scores remained stable over almost
four years, even among those who reported a change in
health status [23]. As no measure of the perceived sever-
ity of their disease was collected, we were not able to
specifically assess how this may have influenced beliefs
over time, although a switch from oral chelation to DFO
is often precipitated by increased disease severity, and
was not associated with any change in beliefs.
Parents expressed significantly higher levels of both
necessity and concern compared to children, and neces-
sity and concern beliefs increased with age. This most
likely reflects maturation and the attendant worry about
long-term effects. Gender, racial, and international dif-
ferences are not well understood, but may be reflective
of the general population rather than thalassemia specific.
It is concerning that patients on combination chelation
therapy express lower necessity towards both chelators,
though this may be expected as need for combination
chelation is sometimes due to iron overload resulting
from prior non-adherence to monotherapy. Alternatively,
combined outcome may be more important to the pa-
tient, which may not be reflected by separate beliefs.
Association with adherence
Correlations between adherence to treatment and the
Specific-Necessity and Specific-Concerns scales, along
with their difference (cost-benefit analysis) have been
reported in diverse diseases and countries and across
multiple measures of adherence [1-14,17,18]. This asso-
ciation has been found in a range of countries includ-
ing the US, UK, Germany, Italy, Sweden, Norway, the
Netherlands, and Australia. Methods of quantifying
adherence have included self report, the Reported Ad-
herence to Medication (RAM) scale, the Medication
Adherence Report Scale (MARS), the Medication Ad-
herence Survey (MAS), pharmacy refill records, serum
concentrations of medication, and urinary drug excre-
tion measurements. Only one other study of Swedish
migraineurs [15] failed to find an association between
necessity/concerns and adherence. This makes the find-
ing of a lack of association between necessity/concerns
and self-reported adherence in thalassemia an important
finding for the study of the adherence pathway.
Our data shows that thalassemia patients fairly univer-
sally understand the necessity of their treatments and
have few concerns compared to other patient popula-
tions. Unlike other diseases, thalassemia patients have
had routine, regular experiences with their treatment
throughout their lives. Given the history of poor ad-
herence in the 1970’s and 1980’s, providers spend a lot
of energy educating patients about the importance of
chelation adherence. These data show that this effort
pays off with high necessity-concern scores. What is
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into adherence action.
Clearly adherence is a complex problem. In a recent
publication, we reported high chelation adherence in this
thalassemia population, with an apparent surge in self-
reported adherence rates with the recent introduction of
alternative choices of oral chelators [24]. However, this
study used adherence self-reports that may overestimate
actual adherence. Using clinical assessments such as
serum ferritin and LIC may better reflect past or present
chelation adherence, but these measures of iron burden
may also reflect inadequate dosing. Complicating the
picture is the observed positive association between con-
cerns with oral chelation and ferritin and LIC that sug-
gests an association of adherence with concerns. There
is also the negative correlation between concerns with
DFO and ferritin that is difficult to interpret, although
anecdotal evidence suggests that patients who choose to
use DFO tend to be older, while younger patients have
to use DFO because of poor compliance.
Overall, problems with administration and side effects
appeared to be common causes of poor chelation adher-
ence [24]. Although side effects are strongly correlated with
the Concerns scale, it appears that side effects themselves
may be the better predictor of adherence, as evidenced by
the association between ferritin, LIC, and non-adherence to
oral chelation with side effects. Thus it appears that thalas-
semia patients may not base adherence on a health cost-
benefit analysis of the necessity of chelation, especially with
DFO, but rather recognize that chelation is absolutely ne-
cessary but sometimes difficult to maintain.
Consistent with a previous study [16], adherence was
found to negatively correlate with perceived personal
sensitivity to medications (Sensitive Soma). Addressing
patients’ beliefs about the tolerability of medications has
the prospect for gains not just in adherence, but also in
quality of life and decreased anxiety/depression, which
have been found to be impaired in thalassemia [25,26].
How to address these beliefs is a challenge because pa-
tient experience of side effects and clinical complications
of thalassemia are not only associated with higher sensi-
tive Soma scores but also impaired quality of life [25].
The BMQ data clearly show that thalassemia patients on
both types of chelators express an understanding of the
need for the drug, but then may simply not use it to the
extent prescribed. This suggests that the tried response
that appears to work for many diseases - more education
– is unlikely to be adequate. What is clear is that patient
beliefs are out of step with their practices. Given this,
the logical intervention would be to deploy strategies
that help patients align their beliefs with their practices.
Anecdotal, unpublished data from the University College
London Thalassemia Program appear to show that
cognitive-behavioral therapy does improve adherenceand long-term outcome in thalassemia. While the costs
of this behavioral intervention can appear to be immedi-
ately expensive, the improved long-term outcome and
reduced need for clinical interventions because of com-
plications due to iron-overload far outweigh this burden.Conclusions
One goal of deploying multiple “quality of life” instru-
ments in the TLC was to measure known social and
behavioral factors that influence patient adherence
behaviors in order to inform intervention. The data from
the deployed set of instruments including the BMQ and
Sensitive Soma clearly reinforce the reality that adher-
ence is a complex and multifaceted problem. This study
has many strengths and is the first study of beliefs in
medications in thalassemia. We were able to analyze a
large, racially diverse, international sample of thalassemia
patients, almost all on transfusion therapy, mostly using
deferoxamine or deferasirox for chelation. This study
also had the advantage of descriptively comparing beliefs
to other disease populations, as well as investigating
associations with QOL, symptoms of anxiety and depres-
sion, and adherence. Finally, the longitudinal cohort
allowed for exploration of changes in beliefs over time,
especially for patients who switched chelators during
follow-up. This study also had several limitations that
may impact its generalizability. First, less adherent
patients may also be less likely to participate in research,
and beliefs in medicine may influence decisions to attend
study visits, thereby potentially skewing the resulting
data towards higher adherence and more positive beliefs
in medicine. Second, adherence was measured from pa-
tient report, which is likely overestimated. Additionally,
the SF-36v2 health survey has only been formally vali-
dated in adults, but we chose to use the instrument on
participants aged 14–17 as well, in order to assess the
adolescent view. Quality of life in children was measured
solely by parent report; additional measurement by child
report would be instructive. Finally, no information on
specific side effects or adherence to transfusion therapy
was collected. As non-adherence to transfusion therapy
results in lower hemoglobin levels, which generally im-
mediately affects how patients feel, it would be of interest
to measure. Additionally, comparison of the beliefs of
thalassemia patients to those with other hematological
diseases would be worthwhile.
Clinically, these findings are instructive. Data suggests
that patients do know about the importance of their
medications. Providers do need to continue to reinforce
the necessity of the clinical regimens, and manage patient
concerns with them. They also need to recognize that pa-
tient adherence is not simply predicated on patients
being better educated, but also learning how to use that
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assessment of individual beliefs regarding thalassemia
treatment can help health providers better motivate their
patients. While change in general beliefs may be hard to
implement, perceived sensitivity to chelation may repre-
sent an opportunity for targeted intervention. Thalas-
semia patients may benefit from perceiving that their
bodies can actually tolerate the prescribed therapy, and
continued efforts to find effective chelators that are pain-
less and without significant side effects seem warranted.
In the meantime, devising strategies and interventions to
help patients effectively cope with side effects might be
ultimately beneficial in lowering body iron burden. As
beliefs were found to differ by age, sex, and race, support
groups mixing patients could be of interest. Despite their
requirement for demanding, multimodal therapy, it is en-
couraging that thalassemia patients have positive views
about medicine, with high belief in their necessity and
relatively low concerns about their therapy.Appendix 1
Beliefs about Medicines Questionnaire (BMQ) Items
Rated: 1=strongly disagree, disagree, uncertain, agree,
strongly agree=5
Scoring: sum of responses to individual items
Higher scores indicate higher agreement with the scale
items
Specific-Necessity: (5–25 points)
My health, at present, depends on my medicines.
My life would be impossible without my medicines.
Without my medicines I would be very ill.
My health in the future will depend on my medicines.
My medicines protect me from becoming worse.
Specific-Concerns: (5–25 points)
Having to take medicines worries me.
I sometimes worry about long-term effects of my medicines.
My medicines are a mystery to me.
My medicines disrupt my life.
I sometimes worry about becoming too dependent on
my medicines.
General-Overuse: (4–20 points)
Doctors use too many medicines.
Natural remedies are safer than medicines.
Doctors place too much trust on medicines.
If doctors had more time with patients they would
prescribe fewer medicines.
General-Harm: (4–20 points)
People who take medicines should stop their treatment
for a while every now and again.Most medicines are addictive.
Most medicines are poisons.
Medicines do more harm than good.
General-Benefit: (4–20 points)
Medicines help many people to live better lives.
In most cases the benefits of medicines outweigh the
risks.
In the future medicines will be developed to cure most
diseases.
Medicines help many people to live longer.
Sensitive-Soma: (5–25 points)
My body is very sensitive to medicines.
My body over-reacts to medicines.
I usually have stronger reactions to medicines than most
people.
I have had a bad reaction to medicines in the past.
Even very small amounts of medicine can upset my body.
Appendix 2
The following institutions and researchers contributed
to the Thalassemia Clinical Research Network Thalas-
semia Longitudinal Cohort data reported in this paper.
Children’s Hospital, Boston: Ellis Neufeld, MD, PhD,
Principal Investigator, Jennifer Braunstein, NP, Research
Nurse, Amber Smith, Study Coordinator, Latoya Lashley,
Study Coordinator; Satellite: University of Texas South-
western Medical Center at Dallas, Charles Quinn, MD,
MS, Principal Investigator, Deborah Boger, RN, MSN,
PNP, Study Coordinator, Leah Adix, Study Coordinator,
Sandra Richardson, Study Coordinator; Children's Health-
care of Atlanta, Jeanne Boudreaux, MD, Principal Investi-
gator, Leann Hassen, Study Coordinator; Baylor College
of Medicine, Brigitta Mueller, MD, Principal Investigator,
Bogden Dino, Study Coordinator. Weill Medical College
of Cornell University: Patricia Giardina, MD, Principal
Investigator, Dorothy Kleinert, RN, Research Nurse;
Satellite: Winthrop University Hospital, Mark Weinblatt,
MD, Principal Investigator, Linda Skelly, Study Coordin-
ator. The Children’s Hospital of Philadelphia: Janet
Kwiatkowski, MD, Principal Investigator, Marie Martin,
RN, Research Nurse, Sage Green, Study Coordinator;
Satellite: Children’s Memorial Hospital, Chicago, IL,
Alexis Thompson, MD, Principal Investigator, Janice
Beatty, RN, Research Nurse, Diane Calamaras, RN,
CPNP, Research Nurse, Pauline Hess, study coordinator.
Children’s Hospital at Oakland: Elliott Vichinsky, MD,
Principal Investigator, Dru Foote, NP, Research Nurse,
Nancy Sweeters, Study Coordinator, Olivia Vega, Study
Coordinator; Satellites: Children’s Hospital of Los Angeles,
Thomas Coates, MD, Principal Investigator, Susan Carson,
RN, Research Nurse, Eun Ha Pang, Study Coordinator,
Rachna Khanna, Study Coordinator; Stanford Hospital,
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http://www.hqlo.com/content/10/1/148Michael Jeng, MD, Principal Investigator, Kokil Bakshi,
Clinical Research Associate; Children's and Women's
Health Center of British Columbia, John Wu, Principal
Investigator, Heather McCartney, RN, Research Nurse,
Colleen Fitzgerald, Study Coordinator, Stephanie Badour,
Study Coordinator. Toronto General Hospital, Toronto,
Ontario, Canada: Nancy F. Olivieri, MD, Principal Inves-
tigator, Vivek Thayalasuthan, Study Coordinator; Satel-
lite: Hospital for Sick Children, Isaac Odame, MD,
Principal Investigator, Manuela Merelles-Pulcini, RN,
Study Coordinator. University College London, John
Porter, MD, Principal Investigator, Cindy Bhagwandin,
Study Coordinator; Satellite: Whittington Hospital,
Farrukh Shah, MD, Principal Investigator. NHLBI over-
sight, Kathryn Hassell, MD. Data Coordinating Center:
New England Research Institutes, Sonja McKinlay, PhD,
Principal Investigator, Lisa Virzi, RN, MS, MBA, Project
Director, Felicia Trachtenberg, PhD, Senior Statistician.
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